4.2 Coagulation Cascade Disorders

Coagulation Cascade Disorders, Factor Deficiencies, and von Willebrand Disease

Coagulation disorders generally present with bleeding diatheses that can range from mild, prolonged bleeding after surgery to spontaneous, life-threatening hemorrhages into joints or intracranial spaces. These conditions can be broadly classified based on whether they affect primary hemostasis (platelet and vascular disorders) or secondary hemostasis (coagulation factor deficiencies). Understanding the pathophysiology and laboratory presentation of these disorders is essential for the Medical Laboratory Scientist.

Disorders of Secondary Hemostasis: The Hemophilias

The hemophilias are classic examples of secondary hemostasis disorders. They are characterized by deficiencies in specific coagulation factors of the intrinsic pathway, leading to defective fibrin clot formation. Because the platelet plug forms normally, patients typically do not experience immediate bleeding from superficial cuts (which is controlled by primary hemostasis). Instead, they present with delayed, deep tissue bleeding, classically into the joints (hemarthrosis) and muscles, as the unstable primary plug breaks down without the reinforcing fibrin mesh.

Hemophilia A (Factor VIII Deficiency)

Hemophilia A is an X-linked recessive disorder caused by a quantitative or qualitative deficiency in Factor VIII. It is the most common severe inherited coagulation factor deficiency, affecting approximately 1 in 5,000 male births.

In the coagulation cascade, Factor VIII acts as the essential cofactor for Factor IXa in the intrinsic tenase complex. Without sufficient Factor VIII, the intrinsic pathway cannot adequately activate Factor X, leading to severely impaired thrombin generation and defective clot formation.

Laboratory findings in Hemophilia A include:

• Normal Platelet Count and Normal Prothrombin Time (PT)
• Prolonged Activated Partial Thromboplastin Time (aPTT): Because Factor VIII is part of the intrinsic pathway.
• Normal von Willebrand Factor (vWF) antigen and activity.
• Decreased Factor VIII activity assay.

Hemophilia B (Factor IX Deficiency)

Hemophilia B, also known as Christmas Disease, is clinically indistinguishable from Hemophilia A. It is also an X-linked recessive disorder, but it is caused by a deficiency in Factor IX. Factor IX is a vitamin K-dependent serine protease that, when activated to IXa, forms the catalytic subunit of the intrinsic tenase complex.

Laboratory findings mirror Hemophilia A exactly (prolonged aPTT, normal PT), but specific factor assays will reveal decreased Factor IX activity with normal Factor VIII activity. Both Hemophilia A and B are treated with recombinant factor replacement therapy.

von Willebrand Disease (vWD)

von Willebrand Disease is the most common inherited bleeding disorder, affecting up to 1% of the general population. It is caused by a quantitative or qualitative defect in von Willebrand Factor (vWF). It typically inherits in an autosomal dominant pattern.

Pathophysiology of vWD

vWF serves two critical functions in hemostasis:

1. Primary Hemostasis: It acts as the bridge between the platelet GPIb receptor and subendothelial collagen, mediating platelet adhesion at sites of vascular injury.
2. Secondary Hemostasis: It acts as a carrier protein for Factor VIII in the circulation. vWF binds securely to Factor VIII, protecting it from rapid proteolytic degradation and increasing its half-life significantly.

Because of this dual role, a deficiency in vWF can impair both primary and secondary hemostasis, though the primary hemostatic defect is usually more prominent clinically. Patients typically present with mucocutaneous bleeding (epistaxis, gingival bleeding, menorrhagia) characteristic of platelet disorders, rather than the deep joint bleeding seen in hemophilia.

Types of vWD

• Type 1: The most common form (70-80% of cases). It is a partial quantitative deficiency of functionally normal vWF.
• Type 2: Qualitative defects in vWF. There are several subtypes (2A, 2B, 2M, 2N) based on the specific functional impairment, such as absent high-molecular-weight multimers or abnormal affinity for GPIb.
• Type 3: A rare, severe, virtually total quantitative absence of vWF. Because vWF is entirely absent, Factor VIII is unprotected and rapidly degraded, leading to very low Factor VIII levels and hemophilia-like bleeding symptoms in addition to severe mucocutaneous bleeding.

Laboratory Diagnosis of vWD

The initial screening tests for a bleeding disorder may show a normal or slightly prolonged aPTT (due to concurrent mild Factor VIII deficiency) and a normal PT. The platelet count is typically normal. The definitive diagnosis relies on specific vWF assays:

1. vWF Antigen (vWF:Ag): Measures the total amount of vWF protein in the plasma. It is decreased in Types 1 and 3, but may be normal in Type 2.
2. Factor VIII Activity: Often mildly decreased, but proportional to the vWF level.
3. Ristocetin Cofactor Assay (vWF:RCo): This is the classic functional assay for vWF. Ristocetin is an antibiotic that induces vWF to bind to platelet GPIb in vitro, causing the platelets to agglutinate. In vWD, this ristocetin-induced platelet aggregation is abnormally low or absent because the patient's plasma lacks functional vWF.

By analyzing the ratio of vWF activity (vWF:RCo) to vWF antigen (vWF:Ag), laboratories can differentiate between quantitative (Type 1) and qualitative (Type 2) defects.